[Treatment of advanced breast cancer with alkylating agents]. / Trattamento con alchilanti del carcinoma mammario in fase avanzata]
Minerva Med
; 68(13): 823-30, 1977 Mar 17.
Article
en It
| MEDLINE
| ID: mdl-403484
ABSTRACT
The results obtained in 26 patients suffering from metastatic cancer of the breast no longer sensitive to hormone treatment are reported. The patients were treated with ciclophosphamide (CTX) (500 mg i.v.) once a week and triethylenethiophosphamide (20-30 mg i.m.) (TSPA) every 4 weeks associated with cyclophosphamide as follows CTX--CTX--CTX--CTX+TSPA. 9 objective regressions (34.6%) were observed. Those with objective regression lived 28 months on average (SD 23.45) and those without lived on average 11.41 months (SD 9.89). The difference is statistically significant. Side effects of various types were observed in 7 patients (27%).
Search on Google
Banco de datos:
MEDLINE
Asunto principal:
Neoplasias de la Mama
/
Alquilantes
Límite:
Adult
/
Aged
/
Female
/
Humans
/
Middle aged
Idioma:
It
Año:
1977
Tipo del documento:
Article